Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Everly

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Transplant International : Official Journal of the European Society for Organ Transplantation|January 1, 2019
Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter studyCarrie A Schinstock, Darshana M Dadhania, Matthew J Everly, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|February 18, 2017
Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort studyMatthew J Everly, Kimberly P Briley, Carl E Haisch, et al.
Transplantation Direct|August 21, 2018
Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver RecipientsEric A Engels, Linda W Jennings, Matthew J Everly, et al.
Transplantation|August 6, 2013
Trends and characteristics in early glomerular filtration rate decline after posttransplantation alloantibody appearancePingping Wu, Matthew J Everly, Lorita M Rebellato, et al.
Transplantation|June 10, 2014
Changes in successive measures of de novo donor-specific anti-human leukocyte antigen antibodies intensity and the development of allograft dysfunctionGeorg Dieplinger, Matthew J Everly, Lorita M Rebellato, et al.
Transplantation|February 4, 2014
Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipientsMatthew J Everly, Lorita M Rebellato, Carl E Haisch, et al.
Transplantation|August 5, 2016
Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant RecipientsElaine Y Cheng, Matthew J Everly, Hugo Kaneku, et al.
Clinical Transplants|August 7, 2014
Novel biomarker combination predicts long-term allograft outcomeJunchao Cail, Wei Huang, Paul I Terasaki, et al.
Transplantation|July 21, 2010
Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipientsHargovind L Trivedi, Paul I Terasaki, Aziz Feroz, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|July 4, 2014
Antibody-mediated rejection despite inhibition of terminal complementAndrew Bentall, Dolly B Tyan, Flavia Sequeira, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Transplant International : Official Journal of the European Society for Organ Transplantation|January 1, 2019
Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter studyCarrie A Schinstock, Darshana M Dadhania, Matthew J Everly, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|February 18, 2017
Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort studyMatthew J Everly, Kimberly P Briley, Carl E Haisch, et al.
Transplantation Direct|August 21, 2018
Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver RecipientsEric A Engels, Linda W Jennings, Matthew J Everly, et al.
Transplantation|August 6, 2013
Trends and characteristics in early glomerular filtration rate decline after posttransplantation alloantibody appearancePingping Wu, Matthew J Everly, Lorita M Rebellato, et al.
Transplantation|June 10, 2014
Changes in successive measures of de novo donor-specific anti-human leukocyte antigen antibodies intensity and the development of allograft dysfunctionGeorg Dieplinger, Matthew J Everly, Lorita M Rebellato, et al.
Transplantation|February 4, 2014
Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipientsMatthew J Everly, Lorita M Rebellato, Carl E Haisch, et al.
Transplantation|August 5, 2016
Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant RecipientsElaine Y Cheng, Matthew J Everly, Hugo Kaneku, et al.
Clinical Transplants|August 7, 2014
Novel biomarker combination predicts long-term allograft outcomeJunchao Cail, Wei Huang, Paul I Terasaki, et al.
Transplantation|July 21, 2010
Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipientsHargovind L Trivedi, Paul I Terasaki, Aziz Feroz, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|July 4, 2014
Antibody-mediated rejection despite inhibition of terminal complementAndrew Bentall, Dolly B Tyan, Flavia Sequeira, et al.
Pageof 7